- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model NEW YORK ( TheStreet) -- GlaxoSmithKline (NYSE: GSK) hit a new 52-week high Tuesday as it is currently trading at $47.49, above its previous 52-week high of $47.48 with 733,950 shares traded as of 11:20 a.m. ET. Average volume has been 2.2 million shares over the past 30 days. GlaxoSmithKline has a market cap of $118.03 billion and is part of the health care sector and drugs industry. Shares are up 2.5% year to date as of the close of trading on Monday. GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. The company has a P/E ratio of 14.1, below the average drugs industry P/E ratio of 14.4 and below the S&P 500 P/E ratio of 17.7.